UNSPSC 51182001: Finasteride

This classification denotes a 5 alpha-reductase inhibitor and anti-androgen with the molecular formula C23H36N2O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 57GNO57U7G, chemically known as 4-azaandrost-1-ene-17-carboxamide, n-(1,1-dimethylethyl)-3-oxo-, (5alpha,17beta)- but generally known as finasteride, which bears US NIH Compound Identifier 57363. European Medicines Agency schedules Finasteride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07629MIG.

UNSPSC 51182001 Finasteride is a Commodity code covering generic pharmaceutical products for state and local government health and human services procurement, specifically finasteride and equivalent generic formulations used across public health agencies, correctional facilities, and benefit programs. State and local governments solicit under this code through cooperative purchasing vehicles and individual agency RFPs to secure competitive pricing on multi-source generic medications distributed through established pharmaceutical wholesalers. Issuing bodies include state departments of health and human services, state prison systems, county public health offices, and municipal health clinics participating in cooperative purchasing alliances. The work involves vendor qualification, NDC and product specification compliance, pricing negotiation across multiple net-price and WAC-minus formats, and fulfillment through authorized wholesaler networks with chargeback systems.

Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (S1070000015802) on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products effective July 1, 2026, with proposals due March 26, 2026. The solicitation requires vendors to maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, Morris & Dickson Co., LLC), certify cGMP and Drug Supply Chain Security Act compliance, submit detailed NDC and product-specification documentation in CSV format, maintain $5 million commercial general liability and $2 million network security and privacy liability coverage, and accept a 3 percent administrative fee on all purchases. Evaluation weights 75 percent on price competitiveness, 10 percent on fixed pricing, and 5 percent each on administrative compliance, EDI capability, and acceptance of the 3 percent administrative fee. Contract term is two years for new vendors with optional extensions at MMCAP's discretion, while incumbent vendors align with existing expiration dates through June 30, 2028.